Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

TORONTO, ONTARIO--(Marketwired - Oct. 16, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
October 11, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Welcomes Dr. Helen Tayton-Martin to Its Board of Directors

TORONTO, ONTARIO--(Marketwired - Oct. 11, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
August 11, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO--(Marketwired - Aug. 11, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
July 05, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Provides Update on Small Molecule Programs

TORONTO, ONTARIO--(Marketwired - July 5, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
June 28, 2017 15:45 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Partial Exercise of Over-Allotment Option

TORONTO, ONTARIO--(Marketwired - June 28, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
June 07, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Expands Clinical Trial With TTI-621 to Include Combination With PD-1 Blockade

TORONTO, ONTARIO--(Marketwired - June 7, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company, today announced that based upon promising...
June 01, 2017 16:10 ET | Source: Trillium Therapeutics Inc.

Trillium Closes US$30 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

TORONTO, ONTARIO--(Marketwired - June 1, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
May 31, 2017 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

TORONTO, ONTARIO--(Marketwired - May 31, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
May 26, 2017 16:05 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Voting Results from the Annual Meeting of Shareholders

TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
May 26, 2017 08:30 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares

TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...